Get the Stockscreener App
2.76
3.37%
0.09
After Hours:
2.76
Zentalis Pharmaceuticals Inc stock is traded at $2.76, with a volume of 701.83K.
It is up +3.37% in the last 24 hours and up +20.26% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$2.67
Open:
$2.81
24h Volume:
701.83K
Relative Volume:
0.59
Market Cap:
$195.77M
Revenue:
$26.87M
Net Income/Loss:
$-137.06M
P/E Ratio:
-1.4463
EPS:
-1.9083
Net Cash Flow:
$-125.25M
1W Performance:
+7.39%
1M Performance:
+20.26%
6M Performance:
+68.29%
1Y Performance:
+165.38%
1-Day Range:
$2.71
$2.904
1-Week Range:
$2.3901
$2.904
52-Week Range:
$1.01
$3.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
2.76 | 189.39M | 26.87M | -137.06M | -125.25M | -1.9083 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Resumed | Wells Fargo | Equal Weight |
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
ZNTL Should I Buy - Intellectia AI
Zentalis Pharmaceuticals PAO sells $7.8k in stock - Investing.com
Zentalis Pharmaceuticals announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
ZNTL PE Ratio & Valuation, Is ZNTL Overvalued - Intellectia AI
Sentiment Review: Is Zentalis Pharmaceuticals Inc currently under institutional pressure2026 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Brokers Issue Forecasts for ZNTL FY2030 Earnings - MarketBeat
Guggenheim Reiterates Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by Wall Street Zen to "Sell" - MarketBeat
TD Cowen reiterates Zentalis Pharmaceuticals stock Buy rating By Investing.com - Investing.com Canada
TD Cowen reiterates Zentalis Pharmaceuticals stock Buy rating - Investing.com
Zentalis Pharmaceuticals' (ZNTL) "Buy" Rating Reiterated at Guggenheim - MarketBeat
Oppenheimer reiterates Zentalis stock rating on ovarian cancer drug By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Zentalis stock rating, $10 target By Investing.com - Investing.com Canada
Can Zentalis Pharmaceuticals Inc expand its profit marginsWeekly Market Outlook & Real-Time Sentiment Analysis - baoquankhu1.vn
H.C. Wainwright Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Zentalis Pharmaceuticals 2025 Annual Report: Azenosertib Development, Strategic Restructuring, and Competitive Positioning - Minichart
Zentalis Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zentalis (ZNTL) centers strategy on azenosertib for Cyclin E1-positive ovarian cancer - Stock Titan
Zentalis Pharmaceuticals 10-K: $0 Revenue, $(137.1)M Net Loss - TradingView
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Earnings Results - MarketBeat
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates - Bitget
Zentalis Pharmaceuticals (Nasdaq: ZNTL) cuts costs, extends cash runway into 2027 - Stock Titan
Investment Recap: Can Zentalis Pharmaceuticals Inc expand its profit margins2026 Reactions & Weekly High Potential Alerts - baoquankhu1.vn
ZNTL SEC FilingsZentalis Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Intraday: Can Zentalis Pharmaceuticals Inc keep up with sector leaders2026 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Profit Recap: Does Zentalis Pharmaceuticals Inc have a sustainable dividendEarnings Beat & Consistent Income Trade Ideas - baoquankhu1.vn
Zentalis Pharmaceuticals Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
ZNTL Stock Price, Quote & Chart | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Now Covered by Analysts at Wells Fargo & Company - Defense World
Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday - MarketBeat
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Bitget
Zentalis Pharmaceuticals to Present Two Posters at the - GlobeNewswire
Tech Rally: Can Zentalis Pharmaceuticals Inc expand its profit margins - baoquankhu1.vn
Wells Fargo & Company Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) - MarketBeat
Wells Fargo assumes coverage on Zentalis stock with $5 target By Investing.com - ca.investing.com
Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Almitas Capital LLC - MarketBeat
ZNTL Earnings History & Surprises | EPS & Revenue Results | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
Squadron reports 3,676,900-share stake in Zentalis (ZNTL) - Stock Titan
Aug PreEarnings: What is the implied volatility of BlackRock Municipal Income TrustQuarterly Portfolio Review & Safe Capital Growth Tips - baoquankhu1.vn
Loss Report: Is Alector Inc a strong growth stock2025 Macro Impact & AI Driven Price Forecasts - baoquankhu1.vn
ZNTL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Is Zentalis Pharmaceuticals Inc. likely to announce a buybackMarket Activity Recap & Trade Opportunity Analysis - mfd.ru
Rate Cut: Can Zentalis Pharmaceuticals Inc. expand its profit marginsBear Alert & Proven Capital Preservation Methods - mfd.ru
Layoff Watch: Can Zentalis Pharmaceuticals Inc keep up with sector leadersMarket Performance Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - Bitget
Aug PostEarnings: Is ASTS stock heavily shortedJuly 2025 PreEarnings & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon - Defense World
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
1.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):